ClinicalTrials.gg
CompletedNCT03670095Updated Feb 29, 2024

Study in Healthy Subjects to Compare Two Tablet Formulations of Memantine (Ebixa®) in Fasted and Fed Conditions

A Phase 1 interventional study of Lactose-free memantine and Memantine in Healthy, sponsored by H. Lundbeck A/S. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-29.

Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate the release of memantine into the bloodstream of two different formulations: one formulation containing lactose and one without lactose.

Read the detailed description

The study consists of two cohorts: A1 and A2.

Subjects in Cohort A1 will be administered the investigational medicinal product (IMP) in a fasted state and subjects in Cohort A2 will be administered the IMP in a fed state.

Each subject will change cohort during study participation, so that dosing will be done over two periods: either first fed and then fasted, or first fasted and then fed. The two periods will be separated by a period of 28 days (+7 days) where no investigational medicinal product is given.

All subjects will be confined to the clinic from one day prior to dosing until Day 4 (72 hours post-dose) in each dosing period.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy men and women ≥18 years of age with a (BMI) ≥18.5 and ≤28 kg/m2.
  • Women must be non-pregnant and non-lactating.

Exclusion criteria

Exclusion Criteria:

  • The subject has any concurrent disorder that may affect the particular target or absorption, distribution, or elimination of the IMP.

Other in- and exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Lactose-free memantine tablet

    (treatment A - test) - 10 mg; orally as a single dose in fed and fasted state

    Drug: Lactose-free memantine

  • Experimental
    Lactose-containing memantine tablet (Ebixa®)

    (treatment B - reference) - 10 mg, orally as a single dose in fed and fasted state

    Drug: Memantine

Interventions

  • DrugLactose-free memantine

    Lactose-free memantine tablet, 10 mg; orally as a single dose

  • Lactose-containing memantine tablet, 10 mg, orally as a single dose

    Also known as: Ebixa®

06

What researchers measure

Primary outcomes

  1. AUC0-72h in fed state for test and reference treatment

    Area under the memantine plasma concentration-time curve

    Time frame: From zero to 72 hours post dose

  2. AUC0-72h in fasted state for test and reference treatment

    Area under the memantine plasma concentration-time curve

    Time frame: From zero to 72 hours post dose

  3. Cmax of memantine in fed state for test and reference treatment

    Maximum observed plasma concentration of memantine

    Time frame: From zero to 72 hours post dose

  4. Cmax of memantine in fasted state for test and reference treatment

    Maximum observed plasma concentration of memantine

    Time frame: From zero to 72 hours post dose

Secondary outcomes

  1. tmax in fed state for test and reference treatment

    Nominal time corresponding to the occurrence of Cmax

    Time frame: From zero to 72 hours post dose

  2. tmax in fasted state for test and reference treatment

    Nominal time corresponding to the occurrence of Cmax

    Time frame: From zero to 72 hours post dose

07

Study locations

1 site
  • Shuguang Hospital, Shanghai TCM University
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Dec 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2018
First posted
Sep 13, 2018
StartActual
Aug 28, 2018
Primary completionActual
Dec 24, 2018
CompletionActual
Dec 24, 2018
Last update
Feb 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03670095
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Sep 13, 2018
Start date
Aug 28, 2018
Primary completion
Dec 24, 2018
Completion
Dec 24, 2018
Last update
Feb 29, 2024

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Memantine

Start the discussion